These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 10916760)

  • 1. Feasibility of the adoptive transfusion of allogenic human leukocyte antigen-matched natural killer cells in patients with renal cell carcinoma.
    Frohn C; Doehn C; Durek C; Böhle A; Schlenke P; Jocham D; Kirchner H
    J Immunother; 2000; 23(4):499-504. PubMed ID: 10916760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
    Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
    Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer Cells.
    Machino T; Okoshi Y; Miyake Y; Akatsuka Y; Chiba S
    Immunol Invest; 2012; 41(8):831-46. PubMed ID: 22676066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes.
    Schleypen JS; Von Geldern M; Weiss EH; Kotzias N; Rohrmann K; Schendel DJ; Falk CS; Pohla H
    Int J Cancer; 2003 Oct; 106(6):905-12. PubMed ID: 12918068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells.
    Moretta A; Sivori S; Vitale M; Pende D; Morelli L; Augugliaro R; Bottino C; Moretta L
    J Exp Med; 1995 Sep; 182(3):875-84. PubMed ID: 7650491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.
    Arai S; Meagher R; Swearingen M; Myint H; Rich E; Martinson J; Klingemann H
    Cytotherapy; 2008; 10(6):625-32. PubMed ID: 18836917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective study of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced renal cell cancer.
    Lin M; Xu K; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L
    Immunol Lett; 2017 Apr; 184():98-104. PubMed ID: 28274792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of a new approach of immunotherapy with allogenic (111)In-labelled NK cells in patients with renal cell carcinoma.
    Meller B; Frohn C; Brand JM; Lauer I; Schelper LF; von Hof K; Kirchner H; Richter E; Baehre M
    Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):403-7. PubMed ID: 14685783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.
    Ohira M; Ohdan H; Mitsuta H; Ishiyama K; Tanaka Y; Igarashi Y; Asahara T
    Transplantation; 2006 Dec; 82(12):1712-9. PubMed ID: 17198265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer receptors on CD8 T cells and natural killer cells from different HLA-C phenotypes in melanoma patients.
    Campillo JA; Martínez-Escribano JA; Moya-Quiles MR; Marín LA; Muro M; Guerra N; Parrado A; Campos M; Frías JF; Minguela A; García-Alonso AM; Alvarez-López MR
    Clin Cancer Res; 2006 Aug; 12(16):4822-31. PubMed ID: 16914567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings.
    Clausen J; Kircher B; Auberger J; Schumacher P; Ulmer H; Hetzenauer G; Wolf D; Gastl G; Nachbaur D
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):273-80. PubMed ID: 19857587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional advantage of educated KIR2DL1(+) natural killer cells for anti-HIV-1 antibody-dependent activation.
    Gooneratne SL; Center RJ; Kent SJ; Parsons MS
    Clin Exp Immunol; 2016 Apr; 184(1):101-9. PubMed ID: 26647083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer cells as a therapeutic tool in mismatched transplantation.
    Ruggeri L; Capanni M; Mancusi A; Aversa F; Martelli MF; Velardi A
    Best Pract Res Clin Haematol; 2004 Sep; 17(3):427-38. PubMed ID: 15498714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expansion of NKG2A-LIR1- natural killer cells in HLA-matched, killer cell immunoglobulin-like receptors/HLA-ligand mismatched patients following hematopoietic cell transplantation.
    Rathmann S; Glatzel S; Schönberg K; Uhrberg M; Follo M; Schulz-Huotari C; Kaymer M; Veelken H; Finke J; Fisch P
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):469-81. PubMed ID: 20044012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Leukocyte Antigen-G Inhibits the Anti-Tumor Effect of Natural Killer Cells via Immunoglobulin-Like Transcript 2 in Gastric Cancer.
    Wan R; Wang ZW; Li H; Peng XD; Liu GY; Ou JM; Cheng AQ
    Cell Physiol Biochem; 2017; 44(5):1828-1841. PubMed ID: 29224003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors.
    Della Chiesa M; Vitale M; Carlomagno S; Ferlazzo G; Moretta L; Moretta A
    Eur J Immunol; 2003 Jun; 33(6):1657-66. PubMed ID: 12778484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIR and their HLA Class I ligands: Two more pieces towards completing the puzzle of chronic rejection and graft loss in kidney transplantation.
    Littera R; Piredda G; Argiolas D; Lai S; Congeddu E; Ragatzu P; Melis M; Carta E; Michittu MB; Valentini D; Cappai L; Porcella R; Alba F; Serra M; Loi V; Maddi R; Orrù S; La Nasa G; Caocci G; Cusano R; Arras M; Frongia M; Pani A; Carcassi C
    PLoS One; 2017; 12(7):e0180831. PubMed ID: 28686681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics and organ distribution of allogeneic natural killer lymphocytes transfused into patients suffering from renal cell carcinoma.
    Brand JM; Meller B; Von Hof K; Luhm J; Bähre M; Kirchner H; Frohn C
    Stem Cells Dev; 2004 Jun; 13(3):307-14. PubMed ID: 15186726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma.
    Kremer V; Ligtenberg MA; Zendehdel R; Seitz C; Duivenvoorden A; Wennerberg E; Colón E; Scherman-Plogell AH; Lundqvist A
    J Immunother Cancer; 2017 Sep; 5(1):73. PubMed ID: 28923105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphocyte-conditioned medium in combination with interleukin-2 effectively induces antitumour autoimmunity by adoptive transfer of short activated killer (SHAK) cells.
    Buer J; Hilse R; Dallmann I; Grosse J; Kirchner H; Zorn U; Hänninen EL; Franzke A; Duensing S; Poliwoda H
    Cytokines Mol Ther; 1995 Mar; 1(1):39-46. PubMed ID: 9384662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.